Innovative drug development for headache disorders by Jes OlesenInnovative drug development for headache disorders by Jes Olesen

Innovative drug development for headache disorders

EditorJes Olesen, Nabih Ramadan

Hardcover | September 21, 2008

Pricing and Purchase Info

$92.50 online 
$185.00 list price save 50%
Earn 463 plum® points

Prices and offers may vary in store


Ships within 1-3 weeks

Ships free on orders over $25

Not available in stores


Migraine treatment improved considerably with the advent of the 'triptans' in the 1990s. While the drugs used previously for headache treatment had efficacy, some compounds had bothersome side effects and their overuse could lead to severe complications. In the early days of the triptans, itwas widely presumed that migraine was no longer a treatment problem. However, it has gradually been recognized that a significant proportion of patients are not responsive to triptans or do not tolerate them. It is now clear that, even with effective treatment, patients with frequent migraineattacks are not treated well exclusively with acute medications. This is partly because patients are still bothered by the attacks and partly because frequent intake of acute medication may result in medication-overuse headache. These problems have led to a renewed interest in preventive migrainedrugs. Part of the Frontiers in Headache Research series, this book summarizes the several promising new avenues for the development of future drugs for the treatment of migraine, including cortical-spreading depression inhibition, nitric oxide synthase inhibition and calcitonin gene-related peptide (CGRP)receptor antagonism, as well as other potential targets. The book presents frontline knowledge of these evolving modalities as far as it is available in the public domain. It is hoped that readers and their patients will find it exciting to learn about all the novel possibilities, and also that theimpressive research advances in migraine will lead to increased funding, not only of migraine but also of other types of headache.
Jes Olesen is at the Danish Headache Centre, Department of Neurology, Glostrup Hospital, University of Copenhagen.
Title:Innovative drug development for headache disordersFormat:HardcoverDimensions:240 pages, 9.69 × 6.73 × 0.72 inPublished:September 21, 2008Publisher:Oxford University PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0199552762

ISBN - 13:9780199552764

Look for similar items by category:


Table of Contents

Screening models1. Bolette Christiansen, Trine Kvist, Anders A. Jensen and Hans Brauner-Osborne: The human GABA transporter GAT-2 - From cloning to high throughput screening2. Peter Goadsby: Low throughput preclinical models for headache3. Messoud Ashina: Human models - screening modelsTrials methodology4. Peer Tfelt-Hansen: Stricter success criteria, qualitative and quantitative end points: Acute vs. prevention trials5. Carl G.H. Dahlof: Health related quality of life and similar end points6. Michel D. Ferrari: Clinically relevant designs and outcome measures for acute migraine trials7. E. Marchioni, S. Colnaghi, M. Versino, A. Pichiecchio, E. Tavazzi and G. Nappi: Effectiveness of different steroid dosage in Tolosa-Hunt syndrome with different phenotypes: some critical points about the new HIS classification8. Jes Olesen: Discussion summary: Trials methodologyNO and spreading depression modulators9. Boris A. Chizh: Inducible nitric oxide synthase and development of new migraine treatments10. Kevin C. Brennan and Andrew C. Charles: Mechanisms of cortical spreading depression as targets for migraine therapy11. Peter R. Blower and Paul C. Sharpe: Tonabersat12. Nabih Ramadan: Discussion Summary: NO and spreading depression modulatorsCGRP and 5-HT modulators13. Jes Olesen and Inger Jansen-Olesen: Calcitonin gene-related peptide (CGRP): relevance for migraine14. Pramod Saxena: New 5-HT related drug targets15. L. Juhl, L. Edvinsson, J. Olesen, I. Jansen-Olesen: Effect of two novel CGRP-binding compounds in a closed cranial window rat model16. Jacob Moller Hansen, Alexandra Maria Rahmann, Troels Wienecke, Jes Olesen, Messoud Ashina: Vasoactive intestinal polypeptide is unlikely to be a target for headache and migraine treatment17. Rigmor Jensen: Discussion Summary: CGRP and 5-HT modulatorsIon Channel modulators and antiepileptics18. Arn M.J.M. van den Maagdenberg: Migraine: from genes to pathophysiology - transgenic mouse models of migraine19. Inger Jansen-Olesen and Kenneth Beri Ploug: Katp channels and migraine20. Michael Rogawski: Antiepileptic drugs and migraine21. Pramod Saxena: Discussion Summary: Ion channel modulators and antiepilepticsOther future targets for headache therapy22. Kirk W Johnson, Eric S. Nisenbaum, Michael P. Johnson, Donna K. Dieckman, Amy Clemens-Smith, Edward R Siuda, Colin P. Dell, Veronique Dehlinger, Kevin J. Hudziak, Sandra A. Filla, Paul L. Ornstein, Nabih M Ramadan and David Bleakman: Innovative drug development for headache disorders - Glutamate23. Beatriz Fioravanti and Todd Vanderah: The modulation of TRPV1 channels by cannabinoid1 receptors24. Christian Waeber: Future targets for headache therapy: Prostanoids25. Cristina Tassorelli, Rosaria Greco, Armando Perrotta, Simona Buscone, Giorgio Sandrini, Giuseppe Nappi: Role of anandamide in the modulation of nitroglycerin-induced hyperalgesia - a study in the rat